BioSpace News Archive

Oncorus, Inc. (Nasdaq:ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, announced today that Theodore (Ted) A. Asbhurn, M.D., Ph.D., President and Chief Executive Officer, will participate in fireside chats at two upcoming investor conferences

A team from the Institut national de la recherche scientifique has demonstrated the effectiveness of an inexpensive molecule to fight antibiotic-resistant strains of the bacteria responsible for gonorrhea and meningococcal meningitis.

Vivacelle Bio, Inc. today announces the Department of Defense awarded $5.3 million (USD) dollars for the clinical trial of VBI-S, an intravenously injected fluid based upon Vivacelle Bio’s phospholipid nanoparticle technology for the treatment of septic shock due to various pathogens including COVID-19, other viruses and/or bacteria

Heska Corporation (NASDAQ: HSKA - News; “Heska” or the “Company”), a leading global provider of advanced veterinary diagnostic and specialty products, announced that Kevin Wilson, Heska’s President & Chief Executive Officer, will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on Tuesday, December 1, 2020.

Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced that Craig Thompson, President and Chief Executive Officer, will present at the Piper Sandler 32nd Annual Healthcare Conference and participate in one-on-one meetings with investors

Dario’s top-rated digital diabetes tools and coaching will be available to eligible employees and their dependents starting January 1, 2021

QYNAPSE Inc. a medical technology company commercializing the most advanced artificial intelligence neuroimaging platform, is pleased to sponsor the 106th Radiology Society of North America (RSNA) Annual Meeting – the most important week in radiology.

Ibex Medical Analytics, a pioneer in artificial intelligence (AI)-based cancer diagnostics, today announced the addition of David Shulkin, M.D., and Joe Robinson to its advisory board.

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will participate in the Piper Sandler 32 nd Annual Virtual Healthcare Conference.

F-star Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announces the authorization of the Clinical Trial Application (CTA) in Spain for the initiation of a Phase 1, open label, first-in-human clinical study of FS222. FS222 is a potentially best-in-class bispecific antibody targeting CD137 (4-1BB) and PD-L1.